Description
Brazil
Canada - English
Canada - Français
Deutschland
France
Ελλάδα
Ireland
Latin America
Spain
United Kingdom
日本
See All
For a refined risk estimateof local recurrence
Primary study group results were presented at ASCO 2018.
Help Stage II colon cancer patients understand the power of genomics
In a large clinical data setGPS increased AS utilzation
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test.
NOTE: If you need to submit more than 5 new users, please contact Customer Service.
The first and only test to identify patients with metastatic castration resistant prostate cancer who will not respond to AR-targeted therapies. The Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen-receptor (AR) therapies such as abiraterone and enzalutamide. Learn more about the test→
If you are unsure, please select "No".
Have a specific question? Want to keep up with our latest news? We're here for you.
We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.